Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-73305 in diabetic macular edema
NCT05301751Phase 2Completed
- Sponsor
- Allgenesis Biotherapeutics
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of AG-73305 in diabetic macular edema (DME), sponsored by Allgenesis Biotherapeutics. Started May 2022; status: completed.
02
Drugs
AG-73305
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05301751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301751.